Researchers evaluating global cancer patterns have estimated the lifetime incidence and mortality risks of cervical, ovarian, and endometrial cancers across 185 countries in 2022, identifying pronounced disparities linked to socioeconomic development.
The investigation utilized global estimates from GLOBOCAN 2022 alongside demographic data from the United Nations World Population Prospects 2022. Using life-table methods adjusted for competing mortality, the authors calculated two primary metrics: lifetime incidence risk (LRI) and lifetime mortality risk (LRM).
To assess how risk profiles varied globally, the study stratified countries by national income level and the Human Development Index. The researchers also examined the ratio of lifetime incidence risk to lifetime mortality risk (LRI-to-LRM ratio) as a descriptive measure of divergence between incidence and mortality, noting that this ratio does not serve as a direct estimate of patient survival.
Among the three evaluated malignancies, cervical cancer demonstrated the strongest inverse gradient with socioeconomic development. The estimated lifetime incidence of cervical cancer ranged from 0.88 percent in high-income countries to 2.95 percent in low-income countries, while the lifetime mortality risk spanned from 0.49 percent in high-income settings to 2.45 percent in low-income nations.
In contrast, endometrial cancer followed the opposite trajectory across development levels, with lifetime incidence reaching 2.73 percent in high-income nations compared to 0.39 percent in low-income nations. Meanwhile, ovarian cancer exhibited a relatively stable incidence across countries, accompanied by a persistent mortality burden.
For all three gynecologic cancers, the ratio of lifetime incidence risk to lifetime mortality risk increased significantly with higher national income levels. However, the authors emphasized that this ecological measure is shaped by diagnostic intensity, data quality, competing mortality, and broader health-system factors. They concluded that lifetime-risk metrics may complement traditional age-standardized rates, helping to align prevention, early detection, and treatment priorities with country-specific health-system capacity.
Subject of Research: Global lifetime incidence and mortality risks of major gynecologic cancers
Article Title: Estimated lifetime risks of major gynecologic cancers across 185 countries in 2022: life-course patterns and social inequalities
Article References: Chen, P., Liu, Q.-F., & Ou-Yang, L. (2026). Estimated lifetime risks of major gynecologic cancers across 185 countries in 2022: life-course patterns and social inequalities. Archives of Public Health. https://doi.org/10.1186/s13690-026-02077-w
Image Credits: AI Generated
DOI: 10.1186/s13690-026-02077-w
Keywords: gynecologic cancers, cervical cancer, ovarian cancer, endometrial cancer, lifetime risk, cancer epidemiology, global health, GLOBOCAN 2022, Estimated, lifetime, risks, major
News Source: Nathaniel Bowman. (November 10, 2026). Study Estimates Lifetime Gynecologic Cancer Risks Across 185 Countries in 2022. Scienmag.



